Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT

Background: Licensed ranibizumab (0.5 mg/0.05 ml Lucentis®; Novartis International AG, Basel, Switzerland) and aflibercept (2 mg/0.05 ml Eylea®; Bayer AG, Leverkusen, Germany) and unlicensed bevacizumab (1.25 mg/0.05 ml Avastin®; F. Hoffmann-La Roche AG, Basel, Switzerland) are used to treat macula...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Philip Hykin, A Toby Prevost, Sobha Sivaprasad, Joana C Vasconcelos, Caroline Murphy, Joanna Kelly, Jayashree Ramu, Abualbishr Alshreef, Laura Flight, Rebekah Pennington, Barry Hounsome, Ellen Lever, Andrew Metry, Edith Poku, Yit Yang, Simon P Harding, Andrew Lotery, Usha Chakravarthy, John Brazier
Format:	Artigo
Jezik:	Inglês
Izdano:	NIHR Journals Library 2021-06-01
Serija:	Health Technology Assessment
Teme:	macular oedema central retinal vein occlusion bevacizumab ranibizumab aflibercept vegf anti-vegf cost-effectiveness retinal non-perfusion randomised controlled trial non-inferiority clinical effectiveness visual acuity intravitreal safety adverse events
Online dostop:	https://doi.org/10.3310/hta25380
Oznake:	Označite Brez oznak, prvi označite!